<DOC>
	<DOCNO>NCT02860715</DOCNO>
	<brief_summary>This Phase 1 , randomize , double-blind , placebo-controlled , single ascend dose study design assess safety , tolerability , pharmacokinetics pharmacodynamics GX-I7 healthy volunteer .</brief_summary>
	<brief_title>Clinical Trial GX-I7 Healthy Volunteers</brief_title>
	<detailed_description>The subject adequately eligible attend clinical trial via screen hospitalized one day prior injection ( Day -1 ) , administer single dose GX-I7 solution subcutaneous injection , discharge Day 3 . After complete scheduled test visit 8 ( Day 28 ) , safety-related data cohort evaluate Independent Safety Monitoring Committee ( SMC ) . Dose escalation proceed principal investigator , medical monitor , sponsor 's mutual approval , refer SMC 's evaluation .</detailed_description>
	<criteria>1 . Subject willing able give inform consent listen character clinical trial 2 . Must 1945 year age , inclusive 3 . Weight 50100kg , BMI 1830kg/m2 4 . Subject adequately able attend study base medical history physical exam , clinically significant abnormality vital sign clinical laboratory value 5 . No clinical abnormality ECG test 6 . Nonsmoker ( smoke use product contain nicotine least one month negative urine test ) 1 . Suspected confirmed malignancy , malignancy history 2 . Any clinically significant acute chronic medical condition require care physician , liver , biliary tract , renal , nervous system ( CNS peripheral ) . respiratory system , endocrine ( diabetes , hyperlipidemia etc ) , cardiovascular ( congestive heart failure , coronary artery disease , myocardial infarction etc ) , hematology , malignancy , urinary disease , mental disorder , musculoskeletal disorder , immune system ( rheumatoid arthritis , lupus etc ) , otorhinolaryngologic diseases 3 . Positive HBsAg , hepatitis C virus ( HCV ) Ab HIV Ab 4 . Are consider schedule undergo surgical dental procedure study 5 . Administered Investigational Product ( IP ) attend clinical study biological equivalent study within recent 3 month 6 . Any Serious adverse drug reaction ( SAR ) vaccine antibiotic , medical history serious allergic diseases 7 . Positive urine drug screen respiratory alcohol screen medical screening checkin 8 . History alcohol , drug , substance abuse past 12 month 9 . Consumption alcohol within 48 hour prior hospitalization 10 . Medications antacid , analgesic , herbal treatment , vitamin , mineral ( except maximum 4 gram acetaminophen ) hormone , steroid , insulin , hypoglycemic drug hormone substitute within 14 day administration 11 . Planning pregnancy donation sperm/disagreeing proper contraception study 3 month follow IP administration 12 . Do vein suitable cannulation multiple venipunctures 13 . Any factor Investigator think increase subject risk participation</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Dose-Limiting Toxicity ( DLT )</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>